Description: Gostin argues that there is indeed a crisis in American health care.

Description: The article describes the Health Sections strategic initiative for Public Health and the role of the actuary.

Description: Rising drug—and, to a lesser extent, health care—costs in Canada are creating long-term challenges for not only governments and employers across Canada but for individuals as well, with no easy answers.

Description: This table displays U.S. adult prevalence of all those obese during 2005–2006 by age, gender and selected ethnic group.

Description: Feature article describing what health actuaries think will be the future role of actuaries in the health care industry.

Description: Feature article with helpful hints on video conferencing and more!

Description: Discussion of steps that can be taken to control costs and future plan design changes. Part 2 of a 2 part series. Issue No. 48.

Description: This article aims to measure the accuracy of official projections.

Description: Social determinants of health (SDoH) have been a topic of growing interest in recent years, yet consensus about what the phrase represents and how health-related social needs should be studied or addressed by employers, health plans, providers and other stakeholders in the business of health care have been lacking. For many, low-income populations come to mind when considering the topic, yet SDoH include a wide range of factors beyond income. Many types of data are available, yet each presents distinct challenges and opportunities for analysis. In this article, we describe some of the underlying context for considering SDoH, as well as some of the potential data sources to consult and challenges to grapple with on this important topic.

Description: Savings from biosimilars have accelerated significantly in the past few years. There has been a number of relatively recent biosimilar launches that can help to shape our expectations of the financial impact that could result from this year’s big event. Savings from biosimilars have accelerated significantly in the past few years. There has been a number of relatively recent biosimilar launches that can help to shape our expectations of the financial impact that could result from this year’s big event.